Trials / Approved For Marketing
Approved For MarketingNCT05463939
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teclistamab | Teclistamab will be administered subcutaneously (SC). |
Timeline
- First posted
- 2022-07-19
- Last updated
- 2025-06-15
Source: ClinicalTrials.gov record NCT05463939. Inclusion in this directory is not an endorsement.